Cepheid is a California-based molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company’s innovative GeneXpert® system provides a rapid, accurate and cost-effective method for the detection of infectious diseases, such as tuberculosis, HIV, hepatitis, and influenza, as well as for identifying genetic variations in cancer. Cepheid’s systems are used by hospitals, laboratories, and clinics worldwide and have played a critical role in improving patient outcomes by enabling fast and accurate diagnoses. The company was founded in 1996 and was acquired by Danaher Corporation in 2016.